It's to help support the facilities that we need to go with clinical products. Our focus has traditionally been on the research-use-only products, but we're now moving into clinical grade products. Our media are in 40 different clinical trials.
We want to be able to do the same for the components that go into vaccines, and testing reagents for the pandemic. We have the capability to do this.